Salivary monitoring of antiepileptic drugs

Journal of Pharmacy Practice

Volumn 20, Issue 2, 2007, Pages 147-157

  Baumann, Robert J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Anticonvulsant medication; Epilepsy; Saliva

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE;

ANTICONVULSANT THERAPY; BINDING AFFINITY; DRUG BINDING; DRUG COST; DRUG EFFICACY; DRUG MONITORING; EPILEPSY; GRAND MAL EPILEPSY; HOME MONITORING; HUMAN; PAIN; PATIENT; PATIENT MONITORING; PH; PHYSICIAN; REVIEW; SALIVA ANALYSIS; SALIVATION; SEIZURE; TREATMENT OUTCOME;

EID: 34548126165     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190007305139     Document Type: Review

References (88)

1. Soldin OP, Soldin SJ Review: therapeutic drug monitoring in pediatrics. Ther Drug Monit. 2002 ; 24: 1-8.
2. Eadie MJ Plasma antiepileptic drug monitoring in a neurological practice: a 25-year experience. Ther Drug Monit. 1994 ; 16: 458-468.
3. Johannessen SI, Battino D., Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003 ; 25: 347-363.
4. Bialer M., Johannessen SI, Kupferberg HJ, Levy RH, Perucca E., Tomson T. Progress report on new antiepileptic drugs: A summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res. 2007 ; 73: 1-52.
5. Faught E. Pharmacokinetic considerations in prescribing antiepileptic drugs. Epilepsia. 2001 ; 42 (suppl 4). 19-23.
6. Dodson WE Special pharmacokinetic considerations in children. Epilepsia. 1987 ; 28 (suppl 1). S56 - S70.
7. Patsalos PN, Froscher W., Pisani F., van Rijn CM The importance of drug interactions in epilepsy therapy. Epilepsia. 2002 ; 43: 365-385.
8. Sabers A., Buchholt JM, Uldall P., Hansen EL Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001 ; 47: 151-154.
9. Hidaka M., Fujita K., Ogikubo T., et al. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug Metab Dispos. 2004 ; 32: 581-583.
10. Williams J., Lawthom C., Dunstan FD, et al. Variability of antiepileptic medication taking behaviour in sudden unexplained death in epilepsy: hair analysis at autopsy. J Neurol Neurosurg Psychiatry. 2006 ; 77: 481-484.
11. Bautista RE, Wludyka P. Driving prevalence and factors associated with driving among patients with epilepsy. Epilepsy Behav. 2006 ; 9: 625-631.
12. Baumann RJ, Wilson JF, Wiese HJ Kentuckians' attitudes toward children with epilepsy. Epilepsia. 1995 ; 36 1003-1008.
13. Rane CT, Dalvi SS, Gogtay NJ, Shah PU, Kshirsagar NA A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy. Br J Clin Pharmacol. 2001 ; 52: 193-195.
14. Eadie MJ Therapeutic drug monitoring-antiepileptic drugs. Br J Clin Pharmacol. 2001 ; 52 (suppl 1). 11S - 20S.
15. Kataoka Y., Makino K., Oishi R. Measurement of anticonvulsants and their metabolites in biological fluids. In: Eadie M, Vajda F, eds. Antiepileptic Drugs Pharmacology and Therapeutics. Berlin, Germany: Springer ; 1999: 173-187.
16. Drobitch RK, Svensson CK Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet. 1992 ; 23: 365-379.
17. Jacobson E. Salivary secretion. In: Johnson L, ed. Gastro-intestinal Physiology. 2 nd ed. St Louis, Mo: CV Mosby ; 1981: 46-54.
18. Sreebny LM Salivary flow in health and disease. Compend Suppl. 1989: S461-469.
19. Gorodischer R., Koren G. Salivary excretion of drugs in children: theoretical and practical issues in therapeutic drug monitoring. Dev Pharmacol Ther. 1992 ; 19: 161-177.
20. Gorodischer R., Burtin P., Hwang P., Levine M., Koren G. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis. Ther Drug Monit. 1994 ; 16: 437-443.
21. Baumann RJ, Ryan M., Yelowitz A. Physician preference for antiepileptic drug concentration testing. Pediatr Neurol. 2004 ; 30: 29-32.
22. Tennison M., Ali I., Miles MV, D'Cruz O, Vaughn B, Greenwood R. Feasibility and acceptance of salivary monitoring of antiepileptic drugs via the US Postal Service. Ther Drug Monit. 2004 ; 26: 295-299.
23. Rylance GW, Moreland TA Saliva carbamazepine and phenytoin level monitoring. Arch Dis Child. 1981 ; 56: 637-640.
24. Grim SA, Ryan M., Miles MV, et al. Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit. 2003 ; 25: 61-66.
25. Day RE, Chambers RE Salivary anticonvulsant levels in children with epilepsy. Br J Clin Pract. 1981 ; 35: 25-29.
26. Thieme T., Fitchen J., Bartos F., Salinsky M., Green T., Holden W. Therapeutic drug monitoring using oral samples collected with the OraSure device. Ann N Y Acad Sci. 1993 ; 694: 337-339.
27. Wagner SA, Slavik M. An individualized plastic intraoral device for the collection of human parotid saliva. Int J Clin Pharmacol Ther Toxicol. 1984 ; 22: 236-239.
28. Kankirawatana P. Salivary antiepileptic drug levels in Thai children. J Med Assoc Thai. 1999 ; 82: 80-88.
29. McAuliffe JJ, Sherwin AL, Leppik IE, Fayle SA, Pippenger CE Salivary levels of anticonvulsants: a practical approach to drug monitoring. Neurology. 1977 ; 27: 409-413.
30. Siegel IA The role of saliva in drug monitoring. Ann N Y Acad Sci. 1993 ; 694: 86-90.
31. Rosenthal E., Hoffer E., Ben Aryeh H., Badarni S., Benderly A., Hemli Y. Use of saliva in home monitoring of carbamazepine levels. Epilepsia. 1995 ; 36: 72-74.
32. Ryan M., Grim SA, Miles MV, et al. Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy. 2003 ; 23: 1550-1557.
33. Jones MD, Ryan M., Miles MV, et al. Stability of salivary concentrations of the newer antiepileptic drugs in the postal system. Ther Drug Monit. 2005 ; 27: 576-579.
34. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985 ; 313: 145-151.
35. Trevathan E., Medina MT, Madrid A. Antiepileptic drugs in developing countries. Lancet. 1998 ; 351: 1210-1211.
36. Nelson E., Powell JR, Conrad K., et al. Phenobarbital pharmacokinetics and bioavailability in adults. J Clin Pharmacol. 1982 ; 22: 141-148.
37. Nishihara K., Uchino K., Saitoh Y., Honda Y., Nakagawa F., Tamura Z. Estimation of plasma unbound phenobarbital concentration by using mixed saliva. Epilepsia. 1979 ; 20: 37-45.
38. Kapetanovic IM, Kupferberg HJ, Porter RJ, Theodore W., Schulman E., Penry JK Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther. 1981 ; 29: 480-486.
39. Fernandez de Gatta MR, Alonso Gonzalez AC, Garcia Sanchez MJ, Dominguez-Gil Hurle A., Santos Borbujo J., Monzon Corral L. Effect of sodium valproate on phenobarbital serum levels in children and adults. Ther Drug Monit. 1986 ; 8: 416-420.
40. Miles MV, Tennison MB, Greenwood RS Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit. 1991 ; 13: 166-171.
41. Cacek AT Review of alterations in oral phenytoin bioavailability associated with formulation, antacids, and food. Ther Drug Monit. 1986 ; 8: 166-171.
42. Loebstein R., Koren G. Clinical relevance of therapeutic drug monitoring during pregnancy. Ther Drug Monit. 2002 ; 24: 15-22.
43. Monks A., Richens A. Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients. Clin Pharmacol Ther. 1980 ; 27: 89-95.
44. Fraser DG, Ludden TM, Evens RP, Sutherland EW 3rd. Displacement of phenytoin from plasma binding sites by salicylate. Clin Pharmacol Ther. 1980 ; 27: 165-169.
45. Browne TR, Szabo GK, Evans JE, Evans BA, Greenblatt DJ, Mikati MA Carbamazepine increases phenytoin serum concentration and reduces phenytoin clearance. Neurology. 1988 ; 38: 1146-1150.
46. Richens A., Dunlop A. Serum-phenytoin levels in management of epilepsy. Lancet. 1975 ; 2: 247-248.
47. Paxton JW, Rowell F., Ratcliffe JG, et al. Salivary phenytoin radioimmunoassay. A simple method of the assessment of non-protein bound drug concentrations. Eur J Clin Pharmacol. 1977 ; 11: 71-74.
48. Liu H., Delgado MR Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet. 1999 ; 36: 453-470.
49. Tsanaclis LM, Allen J., Perucca E., Routledge PA, Richens A. Effect of valproate on free plasma phenytoin concentrations. Br J Clin Pharmacol. 1984 ; 18: 17-20.
50. Pisani FD, Di Perri RG. Intravenous valproate: effects on plasma and saliva phenytoin levels. Neurology. 1981 ; 31: 467-470.
51. Reynolds F., Ziroyanis PN, Jones NF, Smith SE Salivary phenytoin concentrations in epilepsy and in chronic renal failure. Lancet. 1976 ; 2: 384-386.
52. Hooper WD, King AR, Patterson M., Dickinson RG, Eadie MJ Simultaneous plasma carbamazepine and carbamazepine-epoxide concentrations in pharmacokinetic and bioavailability studies. Ther Drug Monit. 1985 ; 7: 36-40.
53. Kamali F., Thomas SH Effect of saliva flow rate on saliva phenytoin concentrations: implications for therapeutic monitoring. Eur J Clin Pharmacol. 1994 ; 46: 565-567.
54. Dodson WE Carbamazepine efficacy and utilization in children. Epilepsia. 1987 ; 28 (suppl 3). S17 - S24.
55. Goodnick PJ Anticonvulsants in the treatment of bipolar mania. Expert Opin Pharmacother. 2006 ; 7: 401-410.
56. Levy RH, Pitlick WH, Troupin AS, Green JR, Neal JM Pharmacokinetics of carbamazepine in normal man. Clin Pharmacol Ther. 1975 ; 17: 657-668.
57. MacKichan JJ, Duffner PK, Cohen ME Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients. Br J Clin Pharmacol. 1981 ; 12: 31-37.
58. Pynnonen S. The pharmacokinetics of carbamazepine in plasma and saliva of man. Acta Pharmacol Toxicol (Copenh). 1977 ; 41: 465-471.
59. Levy RH Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia. 1995 ; 36 (suppl 5). S8 - S13.
60. Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther. 1999 ; 24: 87-92.
61. Patsalos PN, Froscher W., Pisani F., van Rijn CM The importance of drug interactions in epilepsy therapy. Epilepsia. 2002 ; 43: 365-385.
62. Knott C., Reynolds F. The place of saliva in antiepileptic drug monitoring. Ther Drug Monit. 1984 ; 6: 35-41.
63. Bourgeois B. Valproic acid. Clinical efficacy and use in epilepsy. In: Levy RH, Mattson R, Meldrum B, Perucca E, eds. Antiepileptic Drugs. Philadelphia, Pa: Lippincott Williams & Wilkins ; 2002: 808-817.
64. Siemes H., Nau H., Schultze K., et al. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity. Epilepsia. 1993 ; 34: 332-346.
65. Hussein Z., Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol. 1997 ; 43: 457-465.
66. Yuen AW, Land G., Weatherley BC, Peck AW Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol. 1992 ; 33: 511-513.
67. Tomson T., Ohman I., Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia. 1997 ; 38: 1039-1041.
68. de Haan GJ, Edelbroek P., Segers J., et al. Gestation-induced changes in lamotrigine pharmacokinetics: A monotherapy study. Neurology. 2004 ; 63: 571-573.
69. May TW, Rambeck B., Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 1996 ; 18: 523-531.
70. Trnavska Z., Krejcova H., Tkaczykovam, Salcmanova Z, Elis J. Pharmacokinetics of lamotrigine (Lamictal) in plasma and saliva. Eur J Drug Metab Pharmacokinet. 1991 ;Spec No 3: 211-215.
71. Tsiropoulos I., Kristensen O., Klitgaard NA Saliva and serum concentration of lamotrigine in patients with epilepsy. Ther Drug Monit. 2000 ; 22: 517-521.
72. May TW, Korn-Merker E., Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet. 2003 ; 42: 1023-1042.
73. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002 ; 16: 263-272.
74. Miles MV, Tang PH, Ryan MA, et al. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). Ther Drug Monit. 2004 ; 26: 300-304.
75. Kristensen O., Klitgaard NA, Jonsson B., Sindrup S. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurol Scand. 1983 ; 68: 145-150.
76. Theisohn M., Heimann G. Disposition of the antiepileptic oxcarbazepine and its metabolites in healthy volunteers. Eur J Clin Pharmacol. 1982 ; 22: 545-551.
77. Miles MV, Tang PH, Glauser TA, et al. Topiramate concentration in saliva: an alternative to serum monitoring. Pediatr Neurol. 2003 ; 29: 143-147.
78. Doose D., Streeter A. Topiramate. Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson R, Meldrum B, Perucca E, eds. Antiepileptic Drugs. Philadelphia, Pa: Lippincott Williams & Wilkins ; 2002: 727-734.
79. May TW, Rambeck B., Jurgens U. Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit. 2002 ; 24: 366-374.
80. Glauser TA, Miles MV, Tang P., Clark P., McGee K., Doose DR Topiramate pharmacokinetics in infants. Epilepsia. 1999 ; 40: 788-791.
81. Patsalos PN The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol. 2003 ; 25: 123-129.
82. Grim SA, Ryan M., Miles MV, et al. Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit. 2003 ; 25: 61-66.
83. Guo T., Oswald LM, Mendu DR, Soldin SJ Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry. Clin Chim Acta. 2007 ; 375: 115-118.
84. Berry DJ, Beran RG, Plunkeft MJ, Clarke LA, Hung WT The absorption of gabapentin following high dose escalation. Seizure. 2003 ; 12: 28-36.
85. Benetello P., Furlanut M., Fortunato M., et al. Oral gabapentin disposition in patients with epilepsy after a high- protein meal. Epilepsia. 1997 ; 38: 1140-1142.
86. Gartlehner G., Hansen RA, Nissman D., Lohr KN, Carey TS A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol. 2006 ; 59: 1040-1048.
87. Schoenenberger RA, Tanasijevic MJ, Jha A., Bates DW Appropriateness of antiepileptic drug level monitoring. JAMA. 1995 ; 274: 1622-1626.
88. Herkes GK, Eadie MJ Possible roles for frequent salivary antiepileptic drug monitoring in the management of epilepsy. Epilepsy Res. 1990 ; 6: 146-154.